Abstract:Background Glioblastoma, the most common primary malignant tumor of the brain, is associated with poor prognosis. Glioblastoma cells exhibit high proliferative and invasive properties, and glioblastoma stem cells (GSCs) have been shown to play a crucial role in the malignant behavior of glioblastoma cells. This study aims to investigate the molecular mechanisms involved in GSCs maintenance and malignant progression. Methods Bioinformatics analysis was performed based on data from public databases to explore the expression profile of Mitotic arrest deficient 2 like 2 (MAD2L2) and its potential function in glioma. The impact of MAD2L2 on glioblastoma cell behaviors was assessed through cell viability assays (CCK8), colony formation assays, 5-Ethynyl-2ʹ-deoxyuridine (EDU) incorporation assays, scratch assays, and transwell migration/invasion assays. The findings from in vitro experiments were further validated in vivo using xenograft tumor model. GSCs were isolated from the U87 and LN229 cell lines through flow cytometry and the stemness characteristics were verified by immunofluorescence staining. The sphere-forming ability of GSCs was examined using the stem cell sphere formation assay. Bioinformatics methods were conducted to identified the potential downstream target genes of MAD2L2, followed by in vitro experimental validation. Furthermore, potential upstream transcription factors that regulate MAD2L2 expression were confirmed through chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays. Results The MAD2L2 exhibited high expression in glioblastoma samples and showed significant correlation with patient prognosis. In vitro and in vivo experiments confirmed that silencing of MAD2L2 led to decreased proliferation, invasion, and migration capabilities of glioblastoma cells, while decreasing stemness characteristics of glioblastoma stem cells. Conversely, overexpression of MAD2L2 enhanced these malignant behaviors. Further investigation revealed that MYC proto-oncogene (c-MYC) mediated the functional role of MAD2L2 in glioblastoma, which was further validated through a rescue experiment. Moreover, using dual-luciferase reporter gene assays and ChIP assays determined that the upstream transcription factor E2F-1 regulated the expression of MAD2L2. Conclusion Our study elucidated the role of MAD2L2 in maintaining glioblastoma stemness and promoting malignant behaviors through the regulation of c-MYC, suggesting its potential as a therapeutic target.

MAD2 Activates IGF1R/PI3K/AKT Pathway and Promotes Cholangiocarcinoma Progression by Interfering USP44/LIMA1 Complex.

BET Protein Inhibition Evidently Enhances Sensitivity to PI3K/mTOR Dual Inhibition in Intrahepatic Cholangiocarcinoma

MAD2L1 supports MYC-driven liver carcinogenesis in mice and predicts poor prognosis in human hepatocarcinoma

Mitotic Arrest Deficient 2 Like 1 Contributes to Colorectal Cancer Cell Migration, Invasion, and Oxaliplatin Resistance Through the Wnt/β‐Catenin Pathway

The Smad4-MYO18A-PP1A complex regulates β-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma

MAD2L2, a key regulator in ovarian cancer and promoting tumor progression

MLN2238 exerts its anti-tumor effects <i>via</i> regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma

MAD2L2 Inhibits Colorectal Cancer Growth by Promoting NCOA3 Ubiquitination and Degradation

The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming.

MADD Expression in Lung Adenocarcinoma and Its Impact on Proliferation and Apoptosis of Lung Adenocarcinoma Cells

The Promoting Effect and Mechanism of MAD2L2 on Stemness Maintenance and Malignant Progression in Glioma.

Identification of MAD2L1 As a Potential Biomarker in Hepatocellular Carcinoma Via Comprehensive Bioinformatics Analysis

MAD2 Combined with Mitotic Spindle Apparatus (MSA) and Anticentromere Antibody (ACA) for Diagnosis of Small Cell Lung Cancer (SCLC).

Knockdown of PSMC2 contributes to suppression of cholangiocarcinoma development by regulating CDK1

MBD2 regulates the progression and chemoresistance of cholangiocarcinoma through interaction with WDR5

Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression

Molecular profiling reveals potential targets in cholangiocarcinoma

CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization

A PLCB1–PI3K–AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression

Depression of MAD2 Inhibits Apoptosis and Increases Proliferation and Multidrug Resistance in Gastric Cancer Cells by Regulating the Activation of Phosphorylated Survivin.

Targeting of MAD2L1 by Mir‐515‐5p Involves the Regulation of Cell Cycle Arrest and Apoptosis of Colorectal Cancer Cells